Divi's Laboratories Limited Share Price & Analysis
₹7,387.5Updated 22 Jul 2026, 03:30 pm IST
LTP
₹7,387.5
—
Open
₹7,330
High
₹7,398
Low
₹7,219.5
Close
₹7,330
52W High
₹7,390
52W Low
₹5,636
Volume
371K
Lot Size
100
Sector
Healthcare
Market Cap
₹1.9L Cr
Face Value
₹2
Large CapNIFTY 100NIFTY 200NIFTY 500NEXT 50
Price Chart
Fundamentals
P/E
73.4
Sector P/E
54.4
P/B
11.71
EPS
₹93.38
ROE
16.5%
ROCE
22%
D/E Ratio
0
Div Yield
0.41%
Book Value
₹631
+
Strengths
- ✓Strong return on equity (ROE 16.5%)
- ✓Efficient capital deployment (ROCE 22%)
- ✓Virtually debt-free
−
Concerns
- ✗High premium to book value (P/B 11.7x)
- ✗Trading near 52-week high (₹7,390)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
| MAXHEALTH Max Healthcare Institute Limited | ₹1,080 | ₹1.1L Cr | 71.5 | 9.82 | 14.7 | 14.7 | 0.33 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
DIVISLAB · as of Mar 2026
Promoters51.89%
FII18.01%▲0.03
DII20.63%▲0.19
Public9.39%▼0.19
Govt0.09%
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 51.92% | 51.92% | 51.89% | 51.89% | 51.89% | 51.89% |
| FII | 14.85% | 14.68% | 16.16% | 17.25% | 17.98% | 18.01% |
| DII | 21.78% | 22.10% | 21.66% | 20.98% | 20.44% | 20.63% |
| Public | 11.33% | 11.19% | 10.17% | 9.79% | 9.58% | 9.39% |
| Govt | 0.10% | 0.10% | 0.10% | 0.09% | 0.09% | 0.09% |
Corporate Events
Dividend - Rs 30 Per Share
Dividend23 Jul 2026
To consider and approve the financial results for the period ended Jun 30, 2026
Results31 Jul 2026
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend22 May 2026
Dividend - Rs 30 Per Share
Dividend24 Jul 2025
Dividend - Rs 30 Per Share
Dividend1 Aug 2024
Dividend - Rs 30 Per Share
Dividend10 Aug 2023
Latest News
All news →Divi's Labs announces AGM date and dividend record date
*Divi's Labs announces AGM date and dividend record date* — The company has published notice of its 36th Annual General Meeting and set a record date for dividend payout. This is part of routine corporate compliance. No financial surprises or strategic shifts were indicated. 📊 *STOCKS:* DIVISLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
NSE Filing13 Jul
Divi's Labs announces dividend TDS details for FY26
*Divi's Laboratories announces dividend TDS details for FY26.* The company has informed the exchange about the deduction of income tax at source from dividend payments for FY2025-26. This is a routine compliance disclosure related to dividend disbursement. No financial impact on operations or earnings is expected. 📊 *STOCKS:* DIVISLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
NSE Filing11 Jun
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2.6K Cr ▼4.1% | ₹2.7K Cr ▲12.7% | ₹2.4K Cr ▼6.8% | ₹2.6K Cr ▲11.5% | ₹2.3K Cr ▼0.8% | ₹2.3K Cr ▲10.4% | ₹2.1K Cr ▼8.0% | ₹2.3K Cr |
| Op. Profit | ₹890 Cr ▲0.2% | ₹888 Cr ▲21.8% | ₹729 Cr ▼17.7% | ₹886 Cr ▲19.2% | ₹743 Cr ▲3.8% | ₹716 Cr ▲15.1% | ₹622 Cr ▼14.9% | ₹731 Cr |
| OPM | 34.0% ▲3.0% | 33.0% ▲10.0% | 30.0% ▼11.8% | 34.0% ▲6.3% | 32.0% ▲3.2% | 31.0% ▲6.9% | 29.0% ▼9.4% | 32.0% |
| Net Profit | ₹583 Cr ▼15.4% | ₹689 Cr ▲26.4% | ₹545 Cr ▼17.7% | ₹662 Cr ▲12.4% | ₹589 Cr ▲15.5% | ₹510 Cr ▲18.6% | ₹430 Cr ▼20.1% | ₹538 Cr |
| EPS (₹) | 21.96 ▼15.4% | 25.95 ▲26.4% | 20.53 ▼17.7% | 24.94 ▲12.4% | 22.19 ▲15.5% | 19.21 ▲18.6% | 16.2 ▼20.1% | 20.27 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹10.6K Cr ▲12.8% | ₹9.4K Cr ▲19.3% | ₹7.8K Cr ▲1.0% | ₹7.8K Cr ▼13.3% | ₹9.0K Cr ▲28.6% | ₹7.0K Cr ▲29.2% | ₹5.4K Cr ▲9.1% | ₹4.9K Cr ▲27.1% | ₹3.9K Cr ▼4.3% | ₹4.1K Cr |
| Expenses | ₹7.1K Cr ▲11.4% | ₹6.4K Cr ▲13.3% | ₹5.6K Cr ▲4.4% | ₹5.4K Cr ▲6.3% | ₹5.1K Cr ▲23.7% | ₹4.1K Cr ▲15.0% | ₹3.6K Cr ▲16.1% | ₹3.1K Cr ▲17.2% | ₹2.6K Cr ▲0.3% | ₹2.6K Cr |
| Op. Profit | ₹3.4K Cr ▲15.8% | ₹3.0K Cr ▲34.5% | ₹2.2K Cr ▼6.8% | ₹2.4K Cr ▼39.0% | ₹3.9K Cr ▲35.5% | ₹2.9K Cr ▲57.0% | ₹1.8K Cr ▼2.6% | ₹1.9K Cr ▲47.7% | ₹1.3K Cr ▼12.5% | ₹1.4K Cr |
| OPM | 33.0% ▲3.1% | 32.0% ▲14.3% | 28.0% ▼9.7% | 31.0% ▼27.9% | 43.0% ▲4.9% | 41.0% ▲20.6% | 34.0% ▼10.5% | 38.0% ▲15.2% | 33.0% ▼8.3% | 36.0% |
| Other Income | ₹433 Cr ▲24.4% | ₹348 Cr ▲3.9% | ₹335 Cr ▼2.6% | ₹344 Cr ▲207.1% | ₹112 Cr ▲96.5% | ₹57 Cr ▼69.4% | ₹186 Cr ▲20.8% | ₹154 Cr ▲43.9% | ₹107 Cr ▲48.6% | ₹72 Cr |
| Interest | ₹24 Cr ▲700.0% | ₹3 Cr ▼25.0% | ₹4 Cr ▲100.0% | ₹2 Cr ▲0.0% | ₹2 Cr ▲0.0% | ₹2 Cr ▼71.4% | ₹7 Cr ▲40.0% | ₹5 Cr ▲150.0% | ₹2 Cr ▼33.3% | ₹3 Cr |
| Depreciation | ₹463 Cr ▲15.2% | ₹402 Cr ▲6.3% | ₹378 Cr ▲10.2% | ₹343 Cr ▲9.9% | ₹312 Cr ▲21.9% | ₹256 Cr ▲37.6% | ₹186 Cr ▲10.1% | ₹169 Cr ▲19.0% | ₹142 Cr ▲15.4% | ₹123 Cr |
| PBT | ₹3.4K Cr ▲16.2% | ₹2.9K Cr ▲34.8% | ₹2.2K Cr ▼8.7% | ₹2.4K Cr ▼35.7% | ₹3.7K Cr ▲38.2% | ₹2.7K Cr ▲46.6% | ₹1.8K Cr ▼1.9% | ₹1.9K Cr ▲50.7% | ₹1.2K Cr ▼11.8% | ₹1.4K Cr |
| Tax % | 24.0% ▼4.0% | 25.0% ▼3.8% | 26.0% ▲13.0% | 23.0% ▲15.0% | 20.0% ▼23.1% | 26.0% ▲8.3% | 24.0% ▼11.1% | 27.0% ▼6.9% | 29.0% ▲20.8% | 24.0% |
| Net Profit | ₹2.6K Cr ▲17.2% | ₹2.2K Cr ▲36.9% | ₹1.6K Cr ▼12.2% | ₹1.8K Cr ▼38.4% | ₹3.0K Cr ▲49.2% | ₹2.0K Cr ▲44.1% | ₹1.4K Cr ▲1.8% | ₹1.4K Cr ▲54.3% | ₹877 Cr ▼17.3% | ₹1.1K Cr |
| EPS (₹) | 96.73 ▲17.2% | 82.53 ▲36.9% | 60.27 ▼12.3% | 68.69 ▼38.4% | 111.52 ▲49.2% | 74.75 ▲44.2% | 51.85 ▲1.7% | 50.96 ▲54.2% | 33.04 ▼17.3% | 39.95 |
| Div Payout | 31.0% ▼13.9% | 36.0% ▼28.0% | 50.0% ▲13.6% | 44.0% ▲63.0% | 27.0% ▲0.0% | 27.0% ▼12.9% | 31.0% ▲0.0% | 31.0% ▲3.3% | 30.0% ▲20.0% | 25.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹53 Cr ▲0.0% | ₹53 Cr ▲0.0% | ₹53 Cr ▲0.0% | ₹53 Cr ▲0.0% | ₹53 Cr ▲0.0% | ₹53 Cr ▲0.0% | ₹53 Cr ▲0.0% | ₹53 Cr ▲0.0% | ₹53 Cr ▲0.0% | ₹53 Cr |
| Reserves | ₹15.4K Cr ▲3.0% | ₹14.9K Cr ▲10.3% | ₹13.5K Cr ▲6.3% | ₹12.7K Cr ▲8.9% | ₹11.7K Cr ▲26.3% | ₹9.2K Cr ▲27.4% | ₹7.3K Cr ▲5.1% | ₹6.9K Cr ▲17.6% | ₹5.9K Cr ▲10.7% | ₹5.3K Cr |
| Borrowings | ₹90 Cr ▲2150.0% | ₹4 Cr ▲33.3% | ₹3 Cr ▲0.0% | ₹3 Cr ▼25.0% | ₹4 Cr ▼20.0% | ₹5 Cr ▼87.2% | ₹39 Cr ▼63.2% | ₹106 Cr ▲68.3% | ₹63 Cr ▲75.0% | ₹36 Cr |
| Other Liabilities | ₹2.6K Cr ▲35.9% | ₹1.9K Cr ▲3.3% | ₹1.9K Cr ▲14.0% | ₹1.7K Cr ▲1.6% | ₹1.6K Cr ▲10.7% | ₹1.5K Cr ▲24.3% | ₹1.2K Cr ▲21.6% | ₹973 Cr ▲22.1% | ₹797 Cr ▲4.6% | ₹762 Cr |
| Total Liabilities | ₹18.2K Cr ▲7.3% | ₹16.9K Cr ▲9.5% | ₹15.5K Cr ▲7.2% | ₹14.4K Cr ▲8.0% | ₹13.4K Cr ▲24.0% | ₹10.8K Cr ▲26.3% | ₹8.5K Cr ▲6.2% | ₹8.0K Cr ▲18.4% | ₹6.8K Cr ▲10.2% | ₹6.2K Cr |
| Assets | ||||||||||
| Fixed Assets | ₹5.7K Cr ▲4.3% | ₹5.4K Cr ▲14.8% | ₹4.7K Cr ▲0.3% | ₹4.7K Cr ▲9.2% | ₹4.3K Cr ▲16.8% | ₹3.7K Cr ▲33.1% | ₹2.8K Cr ▲33.2% | ₹2.1K Cr ▲4.6% | ₹2.0K Cr ▲28.0% | ₹1.6K Cr |
| CWIP | ₹2.0K Cr ▲98.6% | ₹1.0K Cr ▲31.4% | ₹778 Cr ▲267.0% | ₹212 Cr ▼54.9% | ₹470 Cr ▼33.9% | ₹711 Cr ▼22.7% | ₹920 Cr ▲87.0% | ₹492 Cr ▲310.0% | ₹120 Cr ▼73.0% | ₹444 Cr |
| Investments | ₹67 Cr ▲3.1% | ₹65 Cr ▼20.7% | ₹82 Cr ▲6.5% | ₹77 Cr ▲6.9% | ₹72 Cr | ₹0 Cr ▼100.0% | ₹971 Cr ▼50.1% | ₹1.9K Cr ▲3.0% | ₹1.9K Cr ▲15.8% | ₹1.6K Cr |
| Other Assets | ₹10.4K Cr ▼0.2% | ₹10.4K Cr ▲5.4% | ₹9.9K Cr ▲4.8% | ₹9.4K Cr ▲10.8% | ₹8.5K Cr ▲33.6% | ₹6.4K Cr ▲64.7% | ₹3.9K Cr ▲9.9% | ₹3.5K Cr ▲26.3% | ₹2.8K Cr ▲10.3% | ₹2.5K Cr |
| Total Assets | ₹18.2K Cr ▲7.3% | ₹16.9K Cr ▲9.5% | ₹15.5K Cr ▲7.2% | ₹14.4K Cr ▲8.0% | ₹13.4K Cr ▲24.0% | ₹10.8K Cr ▲26.3% | ₹8.5K Cr ▲6.2% | ₹8.0K Cr ▲18.4% | ₹6.8K Cr ▲10.2% | ₹6.2K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹1.7K Cr ▲31.1% | ₹1.3K Cr ▼48.7% | ₹2.5K Cr ▲28.7% | ₹1.9K Cr ▼1.8% | ₹1.9K Cr ▲60.1% | ₹1.2K Cr ▲27.5% | ₹954 Cr ▲22.9% | ₹776 Cr ▼32.5% | ₹1.1K Cr ▲10.8% | ₹1.0K Cr |
| Investing CF | ₹-804 Cr ▼198.9% | ₹-269 Cr ▲90.1% | ₹-2.7K Cr ▼23.4% | ₹-2.2K Cr ▼3026.7% | ₹75 Cr ▲190.4% | ₹-83 Cr ▲87.9% | ₹-685 Cr ▼43.3% | ₹-478 Cr ▲58.1% | ₹-1.1K Cr ▼180.8% | ₹-406 Cr |
| Financing CF | ₹-799 Cr ▲0.0% | ₹-799 Cr ▼0.3% | ₹-797 Cr ▼49.8% | ₹-532 Cr ▼1420.0% | ₹-35 Cr ▲96.8% | ₹-1.1K Cr ▼343.5% | ₹-246 Cr ▲21.7% | ₹-314 Cr ▼15800.0% | ₹2 Cr ▲100.3% | ₹-631 Cr |
| Net Cash Flow | ₹50 Cr ▼74.1% | ₹193 Cr ▲118.5% | ₹-1.0K Cr ▼28.1% | ₹-816 Cr ▼141.1% | ₹2.0K Cr ▲4746.3% | ₹41 Cr ▲78.3% | ₹23 Cr ▲235.3% | ₹-17 Cr ▼230.8% | ₹13 Cr | ₹0 Cr |
| Free Cash Flow | ₹215 Cr ▼16.7% | ₹258 Cr ▼87.0% | ₹2.0K Cr ▲65.7% | ₹1.2K Cr ▲15.6% | ₹1.0K Cr ▲3042.4% | ₹33 Cr ▼85.1% | ₹221 Cr ▼56.0% | ₹502 Cr ▼35.1% | ₹774 Cr ▲20.6% | ₹642 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106d ▲6.0% | 100d ▲19.0% | 84d ▼15.2% | 99d ▲12.5% | 88d ▼8.3% | 96d ▲11.6% | 86d ▼9.5% | 95d ▲17.3% | 81d ▼4.7% | 85d |
| Inventory Days | 311d ▼14.6% | 364d ▲3.4% | 352d ▲3.2% | 341d ▲3.6% | 329d ▲4.1% | 316d ▼8.9% | 347d ▲10.5% | 314d ▲2.3% | 307d ▲4.8% | 293d |
| Days Payable | 88d ▼6.4% | 94d ▲5.6% | 89d ▼7.3% | 96d ▼17.9% | 117d ▲17.0% | 100d ▲4.2% | 96d ▲0.0% | 96d ▼7.7% | 104d ▲85.7% | 56d |
| Cash Conv. Cycle | 330d ▼10.8% | 370d ▲6.6% | 347d ▲0.9% | 344d ▲14.7% | 300d ▼3.8% | 312d ▼7.1% | 336d ▲7.3% | 313d ▲10.2% | 284d ▼11.8% | 322d |
| Working Capital Days | 192d ▼6.8% | 206d ▲9.6% | 188d ▲6.2% | 177d ▲16.4% | 152d ▼15.6% | 180d ▲6.5% | 169d ▼4.0% | 176d ▲19.7% | 147d ▼7.0% | 158d |
| ROCE | 20.0% ▲25.0% | 16.0% ▼15.8% | 19.0% ▼45.7% | 35.0% ▲9.4% | 32.0% ▲28.0% | 25.0% ▼13.8% | 29.0% ▲31.8% | 22.0% ▼24.1% | 29.0% ▼19.4% | 36.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Divi's Laboratories Limited
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]
Healthcare · Pharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is Divi's Laboratories Limited share price today?▾
Divi's Laboratories Limited (DIVISLAB) is currently trading at ₹7,387.5 on NSE, as of the last market session. Prices update daily after market close on MarketNetra.
Is Divi's Laboratories Limited available in F&O (Futures & Options)?▾
Yes, Divi's Laboratories Limited (DIVISLAB) is part of the NSE F&O segment with a lot size of 100 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Divi's Laboratories Limited 52-week high and low?▾
Divi's Laboratories Limited's 52-week high is ₹7,390 and the 52-week low is ₹5,636. The current price of ₹7,387.5 is 0.0% below the 52W high.
What is Divi's Laboratories Limited P/E ratio?▾
Divi's Laboratories Limited's current P/E ratio is 73.4. This indicates the market is paying ₹73.4 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Divi's Laboratories Limited options?▾
Divi's Laboratories Limited options are traded on NSE with monthly expiry contracts (lot size: 100 shares). To trade DIVISLAB options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.